Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 5/22/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. JoAnn V. Pinkerton

Wrong Dr. JoAnn V. Pinkerton?

Gynecology Researcher

Phone: (434) ***-****  HQ Phone
Email: j***@***.edu
University of Virginia
580 Massie Road
Charlottesville , Virginia 22903
United States

Company Description: The University of Virginia was founded in 1819 by Thomas Jefferson. The cornerstone of the University's first building was laid in 1817, with Thomas Jefferson,...   more

Employment History

  • Medical Director of the Midlife Health Center
    University of Virginia
  • Professor of Obstetrics and Gynecology
    University of Virginia
  • Professor of Obstetrics and Gynecology
    University of Virginia Health Center
  • Principal Investigator
    University of Virginia Health Center
  • Member of the Management
    OBG Management
  • Board Of Editor
    OBG Management
  • Director
    Midlife Health Center
  • Medical Director
    Midlife Health Center
  • Director of Midlife Health
    University of Virginia Health Systems
  • Professor and Vice Chair of Obstetrics and Gynecology
    University of Virginia Health Systems
  • Medical Director of the Midlife Health Center
    University of Virginia , Charlottesville
  • Professor of Obstetrics and Gynecology and Vice Chair of Academic Affairs
    University of Virginia , Charlottesville

Board Memberships and Affiliations


  • MD
  • Medical Doctor degree
    Medical College of Virginia
  • undergraduate degree
    University of Virginia
186 Total References
Web References
Use of potentially risky, non-FDA ..., 25 Mar 2015 [cached]
Use of potentially risky, non-FDA approved hormone therapies may soon be as common as use of FDA-approved hormone therapies, according to a study by University of Virginia gynecology researcher JoAnn Pinkerton.
Furthermore, Pinkerton told BioscienceTechnology, recent consumer and pharmacy data from the above survey "suggest that there has been a sharp increase in the use of compounded menopausal hormone therapies since 2002, and that there is a lack of awareness that these compounded formulations, which require a prescription, are not approved by FDA."
Pinkerton noted that "all" the major medical societies (ACOG, the Endocrine Society, NAM, ASRM) "recommend FDA-approved well-studied therapies as first line due to published data on safety, efficacy, and presence of labels and black box warnings when appropriate. However, some providers may believe the hype and myths that compounded therapies are 'safer than approved therapies' and, 'have no risks' or 'fewer risks' despite the absence of well-controlled clinical trial efficacy and safety data on the compounded products themselves."
In other words, Pinkerton said, "Providers may not be aware of unique risks associated with compounding."
Product risks
There are many dangers here, said Pinkerton. "Unsubstantiated claims lead women to think that these products have no risk, low risk or may even prevent cancer. For example, she said, a compounded form of an estrogen called estriol "has been touted to prevent breast cancer without any data to back up the claim. Estriol is a weak estrogen but has potential to stimulate breast and uterus if dosed high enough."
University of Virginia gynecologist and researcher JoAnn Pinkerton, M.D. (Source: University of Virginia) The lack of a label or any warning about "risks of the hormone therapy, relative and absolute contraindications, along with a lack of understanding of unique risks associated with compounding, may lead to a false sense of safety or security," Pinkerton said.
Furthermore, she said, potential risks of compounded hormone therapies "beyond the lack of rigorous testing, thus limiting safety and efficacy data and lack of appropriate labeling, regulation or monitoring, include possible presence of contaminants, lack of sterility, and concerns of overdosing or underdosing, which could increase health risks such as cancer."
In short, Pinkerton said, FDA-approved menopausal hormone therapies provide "tested and regulated therapy, while compounded therapies provide less tested and less well regulated therapies."
Patients can protect themselves by checking box labels, said Pinkerton.
Pinkerton emphasized, like Lobo, that all major medical societies "with menopausal specialists are unanimous that FDA-approved estradiol and progesterone therapies are preferred."
"Women stopped hormones in droves (after ..., 1 May 2013 [cached]
"Women stopped hormones in droves (after the WHI), but 1 out of 4 restarted," because they were having severe symptoms affecting quality of life, Dr. JoAnn Pinkerton, medical director of the Midlife Health Center at the University of Virginia in Charlottesville, told Reuters Health.
Pinkerton was not surprised by the results of the new study, but said she will add in the potential connection to blood pressure to her discussions with patients and figuring out what path is best for each individual patient, she said.
Pinkerton suggests women with bothersome symptoms sit down with a menopause specialist and discuss the safest options, which include lower doses of estrogen delivered by a gel, patch or cream, and lower or intermittent doses of progesterone. What's right for one woman may not be best for another, she said.
"Just as the decision to go on hormones is dependent on many factors, the decision to go off and stay off can be individualized," Pinkerton said.
Our expert is JoAnn V. ... [cached]
Our expert is JoAnn V. Pinkerton, MD, Professor of Obstetrics and Gynecology at the University of Virginia and Director for the Midlife Division and the Midlife Health Center, a nationally recognized multidisciplinary center for women's midlife health. She is a Past President of the Board of Trustees for The North American Menopause Society ( and serves as Vice Chair of the Board of Directors for the National Women's Health Resource Center (
Board of Directors | Academy of Women's Health, 30 April 2015 [cached]
JoAnn Pinkerton, M.D.
University of Virginia School of Medicine
JoAnn Pinkerton at the NAMS ..., 2 Aug 2015 [cached]
JoAnn Pinkerton at the NAMS Annual Meeting
Other People with the name "Pinkerton":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.